NDAORAL-28TABLET
Approved
Jul 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NORDETTE-28 (ethinyl estradiol; levonorgestrel) by Teva. Approved for pregnancy. First approved in 1982.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORDETTE-28 is an oral combined hormonal contraceptive containing ethinyl estradiol and levonorgestrel, indicated for prevention of pregnancy. It is a classic small-molecule estrogen-progestin formulation that has been a market standard since 1982. The drug works by suppressing ovulation and altering cervical mucus to prevent fertilization.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team size and investment likely declining as generic erosion accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
NORDETTE-28 is a mature, commoditizing product with minimal career growth potential; roles are defense-focused (preserving market share, managing generics, handling reimbursement challenges) rather than growth-oriented. Joining this product team signals a stabilization or transition phase in your pharma career, best suited for professionals managing legacy brands or developing mature-market expertise.
Worked on NORDETTE-28 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.